We examined the hypothesis that prostaglandin inhibition by indomethacin (I) increases infarct size in a conscious dog in which the anatomic risk region, infarct size, and collateral flow can be measured. We randomized 45 instrumented dogs into three groups: 21 were pretreated with I (10 mg/kg i.v.), 10 were given only the vehicle (V) (0.1 M sodium phosphate buffer), and 14 were controls (C). Acute permanent occlusion of the left circumflex (LC) coronary artery was made in the conscious state in all dogs. After the dogs were sacrificed 2 days later, the occluded LC bed was defined by stereoscopic coronary arteriography. The mass of infarct (MI), risk region (R), and left ventricle (LV) were calculated from planimetered areas of weighed transverse sections of LV. Total MI was greater in the I dogs (23.2 ± 2.7 g (SEM), n = 15) than in V dogs (15.6 ± 2.2 g, n = 10,p < 0.05) and C dogs (11.8 ± 1.8 g, n = 10,p < 0.005). The masses of R and LV did not differ significantly between groups. MI was directly related to R in all three groups. The relation was similar for C and V dogs (MI -0.50R -8.07, r = 0.96, n = 20), but the slope was greater (p < 0.001) in I dogs (MI = 1.15R -23.86, r = 0.92, n = 15), indicating that for R of any size, infarct size was greater in I dogs than in C and V dogs. Morphologically, I increased infarct size in both subepicardial and lateral directions within R, and this effect was uniform from base to apex of LV. Hemodynamic changes followed similar trends in all three groups, with slightly higher postocclusion mean arterial pressure (p < 0.05) and heart rate (p < 0.1) in I dogs than V and C dogs. Changes in collateral flow, measured using 9-A radioactive microspheres, were not significantly different in the three groups. The mechanism by which I increases infarct size appears to be related to increased oxygen demands and possible cellular membrane effects rather than effects on collateral flow.
SURVIVAL OF ACUTELY ISCHEMIC MYO-CARDIUM depends on collateral blood supply to the ischemic region after coronary artery occlusion, myocardial oxygen demands, and metabolic and cellular factors. Prostaglandins are vasoactive substances'`synthesized in the heart by the enzyme prostaglandin synthetase4l7 and released locally during myocardial ischemia.8-1" Indomethacin, a potent inhibitor of the synthetic enzyme,'2 has been shown to increase the extent of myocardial injury measured by epicardial ST-segment elevation, and decrease the collateral blood flow to ischemic myocardium after coronary artery occlusion in anesthetized dogs,'3 suggesting that prostaglandins may exert a protective effect on ischemic myocardium. Indomethacin might therefore be expected to increase the ultimate extent of myocardial necrosis.
We examined this hypothesis in the conscious dog, using a model developed for measuring 1) collateral blood flow by the radioactive microsphere technique,"146 2) anatomic infarct size,'7 and 3) the size of the region at risk"8 by postmortem stereoscopic coronary arteriography. '9-20 The results indicate that indomethacin increases infarct size and alters the relationship of necrosis to collateral blood flow. The increase in infarct size in these experiments does not appear to be adequately explained by effects on collateral flow, suggesting that other factors are involved.
Methods

Instrumentation
Fifty mongrel dogs weighing an average of 20 kg were instrumented under general anesthesia through a left lateral thoracotomy. A plastic snare was placed around the left circumflex (LC) coronary artery just past the first large marginal branch, 2-3 cm from the aorta. Plastic catheters were placed in the external jugular vein, external carotid artery and left atrium, and their distal ends were brought out at the back of the neck through a subcutaneous tunnel. Antibiotics were given intramuscularly after surgery. Catheters were filled with heparinized saline and flushed daily with 1000 units of heparin. The 45 dogs surviving instrumentation were allocated randomly into three groups: 21 indomethacin-treated (I), 14 untreated controls, and 10 treated only with 0.1 M sodium phosphate buffer, the indomethacin vehicle (V).
One to 2 weeks after instrumentation, the dogs were brought to the laboratory, placed in a specially designed sling and given 10 mg of morphine intramuscularly for sedation and analgesia. Free flow was established in the catheters. Lead II of the ECG, left atrial and aortic pressures (Statham 23 Pdb) were recorded continuously on a pen recorder.
Myocardial blood flow (MBF) was measured using radioactive microspheres (9 ,u in diameter) with Tween-80 added and labeled with one of five isotopes: 125I 45Ce, 85Sr, 91Nb, or "Sc (3 M Co, Minneapolis).
The microspheres were sonicated mechanically for 5 minutes before each injection of 2 X 106 microspheres into the left atrium over 10 seconds, followed by flushing with 10 ml saline. Reference arterial blood samples were withdrawn at a constant rate of 2.17 ml/min on a calibrated Harvard pump, beginning 30 seconds before injecting microspheres and continuing for 2 minutes thereafter. A first injection of microspheres was made about 60 minutes after the morphine was given. After this resting MBF measurement, the 21 1-treated dogs were injected intravenously (i.v.) with a clear solution of 10 mg/kg indomethacin dissolved in 150 ml of 0.1 M sodium phosphate buffer (pH 7.4) over 5 minutes, while the 10 V-treated dogs were injected with 150 ml of 0.1 M sodium phosphate buffer i.v. over 5 minutes. A second microsphere flow measurement was then made in these two groups of dogs 20 minutes later, by which time the heart rate and arterial and left atrial pressures had stabilized.
Before LC coronary artery occlusion, all dogs were premedicated with 1 mg/kg lidocaine i.v. to prevent ventricular ectopic beats. Three minutes later, the snare was pulled to produce an acute permanent occlusion of the LC coronary artery in the fully conscious dog. Further microsphere flow measurements were made 20 seconds and 1 hour after occlusion in all three groups of dogs. Morphine (3 mg i.v.) was given after the first postocclusion flow measurement, and bolus injections of Xylocaine (1 mg/kg i.v.) were given during periods of increased ectopic activity (greater than five ventricular ectopic beats per minute for 3 minutes or more) for 1 hour after occlusion. The six-limb lead ECG and phasic and mean arterial and left atrial pressures were recorded before and after the flow measurements. The dogs were brought back 2 days later for a final microsphere flow measurement and ECG and hemodynamic recordings in the fully conscious state.
Thirty-nine dogs surviving 2 days were then sacrificed after a lethal dose of anesthetic and the hearts removed, washed free of blood, and weighed.
Delineation of the Risk Region by Postmortem Angiography
The coronary arteries were each cannulated 1) proximal to the site of the left circumflex occlusion, 2) in the left anterior descending coronary artery, and 3) in the right coronary artery. Injections (2-6 ml) of a barium sulphate-gelatin mass containing pigment (Dupont Monastral blue, red and green) were made simultaneously under-controlled pressure (120 mm Hg) to perfuse separately the bed proximal to the LC coronary artery occlusion (green), the left anterior descending (LAD) coronary artery bed (red) and the right coronary artery bed (blue).2' The cavities were then packed with gauze swabs and the heart fixed in 10% formalin to preserve the anatomic detail with cardiac structures in nearly diastolic relationships.
Stereoscopic radiographs of the whole heart were taken and the heart then cut from apex to base into five rings, each 1-1.2 cm wide. These rings were also radiographed and photographed without magnification. The arteriograms were viewed stereoscopically by an observer (GH) who had no knowledge of the treatment given or the gross appearance of the hearts or photographs. In all cases, the LC bed distal to the site of occlusion filled via collaterals. Completeness of the LC occlusion was noted and the lateral boundaries of the region distal to the LC occlusion which was at risk of infarction were marked on the radiographed rings by lines between vascular territories of occluded and nonoccluded beds ( fig. 1 ). This was done by following the course of each coronary branch from ring to ring. Markings of the risk region were then made on coded but unmarked copies of radiographs by a second observer (BB). The markings of the risk regions differed by 1.0 ± 0.3 mm (SEM) (n = 100 observations in 20 dogs) between two observers, indicating good interobserver reproducibility. This difference was only 2% of the width of the risk region at the base and 5% at the apex. On each ring, the marking of the lateral boundary of the risk region represented an average of that on top and bottom layers of the ring. The extent of overlap of occluded and unoccluded beds across the boundary markings was measured and averaged <1 mm in all dogs.
Mapping of the Infarct, Risk Region, and MBF
We weighed the rings of the left ventricle after freeing them from the right ventricle and fatty and valvular tissue. Tracings of each ring and the infarct, identified by gross inspection of the unstained, formalin-fixed specimen, were made on a transparent plastic sheet and checked by two independent observers, neither of whom had knowledge of treatment given. In five dogs, we digitized separately the outlines of infarcts made independently by two observers and found that the areas differed by an average of 3% (n = 20 observations), indicating good interobserver reproducibility. We took transmural samples from 1) the center and lateral margins of the infarct located around the posterior papillary muscle, 2) the adjoining noninfarcted tissue within the territory of the occluded LC coronary artery, and 3) the center of the LAD coronary artery territory, near the anterior papillary muscle, and within the red pigmented area. These samples were subdivided into inner and outer halves which were weighed (range 0.5-1 g in the LC region and 1-2 g in the LAD region), placed in vials containing 10% formalin, and finally counted for radioactivity, together with the reference blood samples in a well-type gamma scintillation counter (Packard Model No 5986) at five energy windows adjusted to the peak emission of the five nuclides. MBF (in ml/min/g) was calculated from the formula: MBF = Cm X RBF/Cr, where Cm = corrected counts per gram in myocardial samples, RBF = reference blood flow (withdrawal rate of the Harvard pump), and Cr = counts in the reference blood B A C sample. We mapped the MBFs for the full thickness, inner and outer halves of myocardium from the center and margins of the infarct, and the center of the nonrisk region supplied by the LAD coronary artery for each dog, as well as for each corresponding left ventricular ring for different dogs.
Tracings of the left ventricular rings from each dog were later superimposed on their radiographs and aligned using six markers: the anterior and posterior papillary muscles, the septal wall, the two junctions with the right ventricle, and the cavity contour. We copied angiographically defined markings of the risk region on the tracings of the corresponding rings. Final tracings were coded and planimetered electronically (Hewlett-Packard Digitizer) by an unbiased technician. We measured the areas of each ring, the infarct, the region at risk, and the infarct within inner and outer halves of the risk region for each heart, and averaged areas of the top and bottom surfaces. We then calculated the ratios of the averaged areas of infarcts and risk regions to the total average area of each ring, and computed weights of the entire infarets and risk regions by multiplying the above ratios by the weights of the corresponding rings. From these calculations, we obtained the following data for each heart: 1) total mass of infarct, 2) total mass of risk region, 3) percent of left ventricle infarcted, 4) percent of left ventricular mass at risk of infarction, and 5) percent of risk region infarcted.
Similar data were obtained for each ring. In addition, we measured dimensions of the infarct within the risk region ( fig. 2 ) so we could map the spatial relationship of the infarct within its risk region for each left ventricular ring from base to apex in the three groups of hearts.
Histology
Histologic sections of the coded tissue samples from the infarcted regions were made in the plane of the planimetered surface and stained with hematoxylin and eosin. Microscopic assessment of the percent of coagulative versus contraction band necrosis22-24 was made by two independent pathologists (GH and BB) on two separate occasions. The pathologists were in close agreement, differing by less than 10% (r = 0.90, n = 130), and total histologic necrosis agreed closely with gross necrosis, the two differing by less than 10% (r = 0.86, n 180). . The method to reconstruct spatially the infarcts and risk regions from base to apex of the left ventricle for the three groups is shown. Measurements were made within the risk region and the infarct in each ring along lines 1-13. A t the lateral borders of the risk region, measurements 1 and 3 were made along the endocardial surface, and thicknesses along 4, 5, 12 and 13. Measurement 2 represents the extent of the infarct along the endocardial surface. The thickness of the infarct was measured at 7, 9 and 11 after dividing the infarct into four equal intervals. The thickness of the uninfarcted epicardial rim was measured along 6, 8 and 10. The sites of topographic measurements were arbitrary and do not reflect sites of sampling for flow.
Statistics
Paired and unpaired t tests were used to calculate the significance of differences within and between groups. Linear regression analysis was done by the least square fit method, and the significance of r values, slopes and intercepts calculated. The 2 by 2 chi square test was used to assess the significance of differences in event frequency between groups.
Results
Of 45 conscious dogs subjected to acute LC coronary occlusion, six developed ventricular fibrillation within 30 minutes after occlusion and died. Two of these early deaths were control dogs (2 of 24 = 8%) and four were I-treated dogs (four of 21, 19%). The difference was not statistically significant (XI = 0.38, NS). Postmortem coronary arteriography was done on all 45 hearts. The size of the risk regions in the early deaths were within the range of values for the respective groups.
In four of the remaining 39 dogs with infarcts, angiography suggested incomplete LC occlusion and they were excluded. Thus, results from 35 dogs with infarcts and good angiograms were analyzed: 10 control, 10 V-treated, and 15 I-treated dogs.
Hemodynamic Changes
Resting heart rate and mean arterial and mean left atrial pressures were similar in the three groups. In the control group, initial heart rate was 92 beats/min, mean arterial pressure 107 mm Hg, and mean left atrial pressure 3.5 mm Hg. After coronary occlusion, there was no significant change in mean arterial pressure in controls. Heart rate and left atrial pressure increased significantly to 117 beats/min and 9.5 mm Hg, respectively, and then fell gradually over the next hour.
After the administration of the vehicle and indomethacin, there was a uniform increase in heart rate, mean arterial pressure and mean left atrial pressure in all dogs for the first 5 minutes; but while heart rate and left atrial pressure returned to normal by 20 minutes, the mean arterial pressure remained mildly elevated compared with resting levels in the Vtreated (1 12 vs 104 mm Hg, p < 0.01) and I-treated (122 vs 113 mm Hg, p < 0.05) dogs. These observations differ from those of Terragno et al.,25 who found no change in mean arterial pressure after 10 mg/kg indomethacin i.v. in conscious dogs, but they used a different vehicle for indomethacin (ethanol and Kreb's solution).
Although heart rate and mean left atrial pressure after occlusion in the V-treated and I-treated dogs were similar to those in the control dog, the mean arterial pressure remained significantly higher 1 hour after occlusion in the I-treated than in V-treated dogs (127 vs 104 mm Hg, p < 0.005) and control dogs (127 vs 108 mm Hg, p < 0.05). Also, the heart rate in the Itreated dogs remained slightly higher 1 hour after occlusion than in V-treated dogs (120 vs 113 beats/min, p < 0.1) and in control dogs (120 vs 108 beats/min, p < 0.05).
Electrocardiographic Changes
The degree of ST-segment elevation in limb-leads (2, 3, and aVF at 1 hour after occlusion was not significantly different in the I-treated compared with V-treated and control dogs combined (2ST = 0.56 + 0.15 mV (SEM) vs 0.37 + 0.11 mV,p < 0.3). Significant Q waves, greater than 0.04 sec and 0.2 mV in leads 2, 3, or aVF, were present in 13 of 15 of the Itreated dogs vs seven of 20 of the V-treated and control dogs combined (chi-squared = 7.352, p < 0.01).
The average number of ventricular premature beats (VPBs) during the hour after occlusion was not significantly different between the I-treated (85 ± 36 VPBs) compared to the V-treated (67 ± 38 VPBs) and control dogs (54 ± 29 VPBs). Twelve, six, and three required Xylocaine in the I-treated, V-treated, and control groups, respectively, and the number of boluses of Xylocaine (20-50 mg i.v.) were 2.8 ± 0.5 in I-treated dogs versus 1.7 ± 0.2 in the Vtreated and control dogs combined (p < 0.1).
Effect of Indomethacin on Infarct Size
Indomethacin significantly increased total infarct size ( fig. 3 ). Total infarct mass averaged 23. 4 . Infarct size is directly related to the size of the risk region. Indomethacin alters the slope of the relation seen in control and vehicle-treated dogs, so that there is more infarct for a risk region greater than about 20 g with indomethacin. There is no infarct when the risk region is less than about 20 g. different between the three groups, being 89 ± 5, 101 ± 6, and 93 ± 3 g, respectively, for the control, V-treated and I-treated dogs.
Effect of Indomethacin on the Relation of Total Infarct Size to the Risk Region
The total mass of the infarct (MI) was directly and closely related to the mass of the risk region (R), i.e., the size of the LC coronary artery bed distal to the occlusion for all three groups (fig. 4) . The The spatial geometry of the infarct within the risk region from base (1) to apex (5) of the left ventricle is similar for control (top) and vehicle-treated (middle) dogs, but significantly altered by indomethacin (bottom). Numbers within the infarcts (stippled) indicate infarct mass/mass ofrisk region as percent. There is more infarct at the base than at the apex in the control and vehicle-treated dogs, and the risk region taper to the apex in all three groups. However, indomethacin increased the infarct size in all rings in a disproportionate fashion toward the apex. 4p <0.001 compared to means for untreated and vehicle-treated groups combined.
CIRCULATION
Abbreviations: C = untreated control group (n = 10); V = vehicle-treated group (n = methacin-treated group (n = 15); LV = left ventricular. therefore combined (MI = 0.50R -8.07, r = 0.96, n= 20). The relation for the I-treated group was equally close (MI = 1.15 R -23.86, r = 0.92, n= 15), but the slope of the relationship was significantly greater (p < 0.001). Thus, there was more infarct for a risk region of a given size after indomethacin. On extrapolation, the horizontal axis intercepts for the control plus V-treated and I-treated dogs were about 20 g, suggesting that no infarcts develop for risk regions less than this size.
The difference in infarct size after indomethacin is also seen when the infarct is expressed as a percent of the risk region rather than as a percent of the left ventricle ( fig. 5 ). The percent of infarct in the risk region is significantly greater after indomethacin (54.9 ± 3.6%) compared with the V-treated (30.6 ± 1.5%, p < 0.001 vs I-treated) and the control dogs (27.6 ± 2.6%, p < 0.001 vs I-treated). The mass of the risk region did not differ significantly among the three groups (figs. 3 and 5).
Effect of lndomethacin on the Spatial Relation of Infarct to Risk Region
Indomethacin altered the relation of infarcts to the respective risk regions in each ring of the left ventricle from the base to the apex of the heart (fig. 6 ). In all three groups (table 1), the bulk of the infarct was found in the basal and middle portion of the heart, but the risk region was also greater in the basal rings. The infarct/risk region ratio was greater in the basal than in the apical rings in all three groups. Indomethacin not only increased the absolute mass of the infarct per ring (p < 0.05 vs V-treated and control dogs), but also increased the infarct/risk region ratio (p < 0.001 vs 10); I = indothe other two groups) and did so in a disproportionate fashion from base to apex (X 1.62 at the base vs 1.91 at the apex, NS). The reconstructed maps of the infarcts within their risk regions ( fig. 6 ) also show a significant rim of uninfarcted myocardium within the risk regions at the lateral margins and subepicardial regions. This is true for all three groups. When the actual maps for each ring are superimposed for the three groups, it is clear that indomethacin increased infarct size uniformly from base to apex and did so both laterally and subepicardially ( fig. 7) . Thus, infarcts with indomethacin tend to be wider as well as more transmural.
Effect of Indomethacin on MBF and Coronary Vascular Resistance
In all three groups, MBF within the risk region fell (p < 0.001) after coronary occlusion ( fig. 8 and table 2). Flow was 1) lower in basal than apical rings, 2) lower in the subendocardial half than in the subepicardial half of the ventricular wall, and 3) lower in the center than at the lateral margins of the infarct. Marginal samples were taken well within the confines of the anatomic risk region and were therefore unlikely to represent a mixture of ischemic and nonischemic tissue fed by unoccluded vessels.
In all three groups, flow in both the central and marginal portions of the infarct increased from 20 seconds to 1 hour to 2 days after occlusion. Changes over the first hour after occlusion are shown in figure 8 . In control dogs flow increased over the first hour in the central area from 0.28 ± 0.09 to 0.41 ± 0.15 ml/min/g (p < 0.1) and in the marginal area from 0.44 ± 0.15 to 0.51 ± 0.15 ml/min/g (p < 0.1). In V- . In all three groups, collateral flow increased over the first hour after occlusion at both centers and margins of the infarct, and flow at the margin was higher than at the center. Differences between groups were not statistically significant. Changesfrom previous values are indicated: *p < 0.05. Two-day flows are not shown. 5 1 cm FIGURE 7. Infarct size is greater in indomethacin-treated (dotted line) than in control and vehicle-treated (thick line) dogs. The increase in infarct size occurs uniformly from base to apex and at both subepicardial and lateral borders within the risk region. Actual scaled maps from figure 7 were superimposed and those of control and vehicle groups averagedfor each ofthefive rings in order to reconstruct this figure. treated dogs, corresponding values were 0.15 ± 0.02 to 0.25 ± 0.04 ml/min/g, (p < 0.025), and 0.31 ± 0.04 to 0.38 ± 0.05 (NS) ml/min/g. In I-treated dogs, flows changed from 0.25 ± 0.06 to 0.37 ± 0.06 ml/min/g (p < 0.05) in the central region, and from 0.62 ± 0.18 to 0.70 ± 0.11 ml/min/g (NS) in the marginal region. None of the differences between the three groups were statistically significant. Figure 9 indicates that for each ring, infarcts were larger for similar levels of coronary collateral flow 1 hour after occlusion. Similar results were found 20 seconds after occlusion. Time-related changes in collateral flow were essentially uniform across the left ventricular wall, since there were no significant changes in the ratio of inner wall flow to outer wall flow for any of the groups.
Flows in the nonrisk region were higher after occlusion in both V-treated and I-treated dogs than in controls (p < 0.1). Over the first hour, flow returned to baseline in V-treated dogs, but remained high in Itreated dogs; the difference was significant (p < 0.05). The higher flow in the latter group might have reflected increased myocardial oxygen demands related to elevated arterial pressure and heart rate. Although flows in the risk region were higher at 2 days than at 1 hour in all three groups, the differences are difficult to interpret. Flows in inner and outer halves of the left ventricular wall at 2 days are shown in table 2. At 2 days, necrosis is essentially complete and-flow at this time probably reflects necrosis rather than determines it. Furthermore, the preocclusion 20second and 1-hour flows from the infarct area may be underestimated due to loss of microspheres from necrotic tissue. 26' 27 Assuming that spheres injected at 2 days, just before sacrifice of the animal, are not "lost" to this extent, the 2-day flow value would be high compared with the earlier flows.
Because arterial pressure after occlusion was higher in I-treated dogs, coronary collateral resistances were calculated and compared among the three groups. Collateral resistance decreased significantly in all groups over the first hour, but no statistically significant differences were found between groups.
Effect of Indomethacin on the Type of Necrosis
In all groups, infarcts were sharply demarcated on gross inspection, and had pale centers with an outer hemorrhagic rim at lateral and subepicardial margins. Larger infarcts had areas of white tissue within the pale centers. All infarcts were centered on the posterior papillary muscle. In five V-treated dogs with medium sized infarcts, the margins of the infarct were more hemorrhagic; in all 15 I-treated dogs, the infarcts appeared to be more hemorrhagic.
In all three groups, histologic examination revealed more contraction band necrosis than coagulative necrosis at the subepicardial and lateral margins of the infarct. In samples taken from the middle ring of the left ventricle, contraction band necrosis, as a percent of total necrosis in marginal samples, was 49 ± 10% in inner vs 83 ± 11% in outer halves (p < 0.005) for the control and V-treated dogs, and 54 ± 8% in inner vs 95 ± 3% in outer halves (p < 0.001) for the Itreated dogs. In the central samples, corresponding values were 24 ± 7% in inner vs 51 ± 10% in outer halves (p < 0.01) for the control and V-treated dogs, and 28 ± 6% in inner vs 57 ± 10% in outer halves (p < 0.005) for the I-treated dogs. The total amount of contraction band necrosis in the infarct was not found to be significantly different in I-treated dogs compared with control and V-treated dogs (59 ± 7% vs 51 ± 8%).
Discussion
There are three major observations in our model. First, the spatial geometry of the infarct within the risk region provides evidence for a functional border zone. Second, increase in infarct size takes place by extension both at lateral and subepicardial margins within the anatomic risk region, so that the volume of "natural salvage" is reduced. Third, the increase in infarct size is evidenced by a significant increase in the slope of the relation of infarct mass to the mass of the risk region seen in control and V-treated dogs (fig. 4) .
The presence of the lateral margin of spared myocardium within the risk region has been questioned by other investigators28 using different 741 VOL 59, No 4, APRIL 1979 methodologies and animal models. Some in-vestigatorS28' 29 have defined the risk region by perfusing the coronary bed distal to the occlusion with colored dyes in saline using a hand-held syringe, but we found this method to be inaccurate because the solution penetrates capillaries, overlaps into other coronary beds, and often leaks outside capillaries, even when injections were made under pressures equal to aortic pressure. When we injected different colored dyes into the two coronary beds simultaneously while keeping monitored pressures equal in the two beds, an intermixing occurred at the boundaries, especially a few minutes after the injections had been made. The size of the risk regions with dye injections is thus dependent on viscosity of the solution and pressure applied during the injection. Pigmented neoprene latex injections used by Lowe et al.'8 overcame the problems of penetration beyond the precapillary level and subsequent displacement of the injectate; however, the unoccluded coronary bed was injected by hand before the occluded bed, so that collaterals developing after occlusion might have led to an underestimation of the risk region. The latter problem might have been circumvented by simultaneous coronary injections under controlled pressure. Postmortem stereoscopic coronary arteriography'9' 20 under controlled pressure permits excellent visualization of coronary vessels. Each vessel can be followed from ring to ring and its territory defined. This method accurately defines the region at risk of infarction after coronary artery occlusion, and interobserver error is less than 5%.
In this study, indomethacin increased the absolute infarct mass as well as infarct size relative to the size of the risk region. The effect could not be attributed to the vehicle used because infarct size was identical in Vtreated and control dogs.
The precise mechanism responsible for the increased infarct size after indomethacin is unclear. There are three possible explanations. Theoretically, increases in myocardial oxygen consumption, decreases in collateral flow, or direct metabolic or cellular effects could have been responsible. The mild increases in mean arterial pressure and heart rate after occlusion we observed in I-treated dogs might have increased myocardial oxygen demands and contributed to the increase in infarct size, although the changes do not seem sufficient to account for the large increase in infarct size observed. One might have expected a decrease in collateral flow related to the inhibition of prostaglandins with vasodilatory properties,1-3 but we did not find that collateral flow was significantly lower with indomethacin. In contrast, Kirmser et al.'3 found that a dose of indomethacin similar to that used in our study decreased collateral flow after occlusion in anesthetized, open-chest dogs. The findings may differ because we used conscious dogs that were not acutely stressed by surgery. Alternatively, indomethacin in our model may have inhibited synthesis of vasodilating and vasoconstricting30 prostaglandins to different degrees or affected the synthesis of other vasoactive substances such as prostacyclins,3" Kinins, or angiotensins. Indomethacin might have acted directly or by inhibition of metabolic and cellular effects of prostaglandins. The finding by Ogletree and Lefer,32 that E-prostaglandins protect ischemic myocardium by stabilizing cardiac lysosomal membranes in open-chest cats, supports the latter view. Inhibition of prostaglandins by indomethacin might therefore be expected to result in lysosomal disruption in the ischemic region. Another possibility is that the unopposed effects of thromboxanes and endoperoxides might have led to an increase in infarct size through an increase in platelet aggregation at the margins of the ischemic region.
The finding by other investigators33 that ibuprofen, another nonsteroidal anti-inflammatory agent, reduces infarct size in rats may relate to differences in the drug used, the species used and experimental protocol. Another possibility is that different inhibitors have different effects on PG-metabolizing enzymes, including prostaglandin synthetase. 34 Due to loss of microspheres from necrotic myocardium,26' flow measurements made at 2 days, before sacrificing the dogs, are not comparable to those made over the first hour after occlusion. In contrast, flows at 20 seconds and 1 hour after occlusion were made so close to each other that it is reasonable to assume that both measurements were subject to an equal amount of sphere loss. However, while such comparisons may be valid within one group, the validity of comparisons between groups is not established. The large intravenous dose of indomethacin used is similar to that used by other investigators to ensure complete inhibition of prostaglandin synthetase in experimental studies of effects on renal25 and cardiac vascular beds.9 13 Observations after such a large dose of indomethacin in the conscious dog cannot be extrapolated to man where much smaller doses are given orally.
In conclusion, we have shown that indomethacin given before coronary occlusion in the conscious dog increases infarct size. This effect is seen at both lateral and subepicardial margins, and is uniform from base to apex of the left ventricle. Changes in collateral flow do not appear to explain this effect adequately, so that changes in myocardial oxygen demands and cellular and metabolic effects of prostaglandins may be involved. Although these observations with indomethacin suggest the hypothesis that prostaglandins may protect acutely ischemic myocardium and reduce ultimate infarct size, further studies are needed to test its validity.
